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Type I-F CRISPR-Cas resistance against virulent
phages results in abortive infection and
provides population-level immunity
Bridget N.J. Watson1,6, Reuben B. Vercoe1, George P.C. Salmond2, Edze R. Westra 3,
Raymond H. J Staals 1,4 & Peter C. Fineran 1,5*
Type I CRISPR-Cas systems are abundant and widespread adaptive immune systems in
bacteria and can greatly enhance bacterial survival in the face of phage infection. Upon phage
infection, some CRISPR-Cas immune responses result in bacterial dormancy or slowed
growth, which suggests the outcomes for infected cells may vary between systems. Here we
demonstrate that type I CRISPR immunity of Pectobacterium atrosepticum leads to suppression
of two unrelated virulent phages, ɸTE and ɸM1. Immunity results in an abortive infection
response, where infected cells do not survive, but viral propagation is severely decreased,
resulting in population protection due to the reduced phage epidemic. Our ﬁndings challenge
the view of CRISPR-Cas as a system that protects the individual cell and supports growing
evidence of abortive infection by some types of CRISPR-Cas systems.
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To respond to the pressure of phage infection, bacteria haveevolved various lines of defence1–3. The adaptive arm ofthese defences is provided by CRISPR-Cas, which provides
immunity through CRISPR RNA guided cleavage of phage gen-
omes4,5. CRISPR-Cas systems are incredibly diverse and are
currently classiﬁed into two major classes (1 and 2), six types
(I–VI) and >30 subtypes6,7 (for recent reviews, see refs. 4,5,8).
Crucially, recent studies revealed that at least some CRISPR-Cas
variants, belonging to types VI and III, induce cell dormancy
through collateral RNA cleavage following target recognition9–13.
Furthermore, it is possible that type V systems induce cell death
through ssDNA cleavage14. In contrast, the most abundant type I
CRISPR-Cas systems, which make up around 60% of all CRISPR-
Cas systems15, as well as the somewhat less common type II
systems, can increase the survival of infected individuals16,17. Yet
type I immunity against some phages resulted in population
decline18. Hence, it appears that immunity mediated by type I
systems may lead to different outcomes for infected cells.
Here we examine the outcome of CRISPR-Cas immunity using
Pectobacterium atrosepticum, which carries a type I–F system,
and two unrelated virulent phages as model systems. We ﬁnd that
CRISPR-Cas immunity reduces the number of cells that release
phages and of those that produce progeny, the burst size is
decreased. Infected cells do not survive phage infection, yet they
reduce phage ampliﬁcation, which provides protection at the
population level. In abortive infection (Abi) systems, phages can
adsorb, but phage replication is interrupted, leading to the death
of the infected cell and the release of few, or no phages19,20.
Consequently, the bacterial population survives19,20. Therefore,
the observed CRISPR-Cas immunity phenotype to virulent phage
infection entirely fulﬁls the deﬁnition of abortive infection. This
has key implications for the way natural selection operates on
CRISPR-Cas21 and is analogous to that observed for other kin-
selected altruistic defences, which also provide population-level
beneﬁts despite the death of the infected individuals.
Results
CRISPR-Cas reduces phage infectious centres and burst size.
To investigate the outcomes of phage infection in the presence of
CRISPR-Cas immunity, we examined the response to phage
infection by P. atrosepticum, which contains a type I–F system
(Fig. 1a)22,23. We used two different phages, ɸTE and ɸM1,
members of the Myoviridae and Podoviridae families, respec-
tively. Phage infectivity was assessed using strains with one or
three phage-targeting spacers in the chromosomal CRISPR arrays
and compared with P. atrosepticum lacking phage-targeting
spacers. CRISPR-Cas provided protection against ɸTE and ɸM1
infection, reducing the efﬁciency of plating (EOP) by at least 10-
fold with one spacer, with additional spacers increasing resistance
to 105-fold with three spacers (Fig. 1b, Supplementary Table 1).
To determine what stage of phage reproduction was impeded, we
investigated the effects of CRISPR-Cas on deﬁned aspects of
infection. CRISPR-Cas caused a decrease in the efﬁciency of
centre of infection (ECOI) formation (Fig. 1c), meaning that for
ɸTE, only 4 or 1% of infected cells released at least one infectious
phage (for the 1 × and 3 × anti-ɸTE strains, respectively). Fol-
lowing ɸM1 infection, only 23 or 6% of cells released phages (for
1 × and 3 × anti-ɸM1, respectively). Next, one-step growth curves
were performed to observe phage growth on the resistant hosts
(Supplementary Fig. 1 and Supplementary Table 1). The average
phage burst size was determined for each host and the number
was signiﬁcantly reduced by CRISPR-Cas (Fig. 1d). For ɸTE,
both the 1 × or 3 × anti-ɸTE strains almost completely sup-
pressed the burst and for ɸM1 it was reduced by >90% on the 3×
anti-ɸM1 strain. As expected, adsorption was unaffected by
CRISPR immunity (Supplementary Fig. 1 and Supplementary
Table 1). Therefore, the P. atrosepticum type I–F CRISPR-Cas
immunity reduced both the number of cells releasing phages and
the average number of phages released per cell.
We previously characterised an Abi system in P. atrosepticum,
ToxIN, which functions as a toxin-antitoxin system24,25. ToxIN
provides protection against both ɸTE and ɸM1 phages, acting as
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Fig. 1 CRISPR-Cas reduces phage infectious centres and burst size.
a Schematic of the type I–F system in P. atrosepticum. C1, C2 and C3
represent CRISPR arrays 1, 2 and 3. b Phage resistance (i.e. efﬁciency of
plating (EOP)), c efﬁciency of centre of infection (ECOI) formation and
d average burst size was assessed for the phage-sensitive WT, anti-ɸ
strains with one (1×) or three (3×) spacers targeting ɸTE and ɸM1 and cells
with ToxIN. In c the red dashed line represents the background level of
phages (in the other panels the limit of detection is below the axis limits).
Phages were added at a multiplicity of infection (MOI) of 0.1 for both c and
d. Data shown is the mean+ one standard deviation (SD). nd, not
detected. Statistical signiﬁcance was calculated using one-way ANOVA
using Dunnett’s multiple comparison test, comparing strains with targeting
spacers to the control with no-targeting spacers. No signiﬁcance was
detected, unless indicated (*p≤ 0.05). All data are provided in
Supplementary Table 1. Source data are provided as a Source Data ﬁle.
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an Abi system, so we included ToxIN to compare the phenotypes
provided by CRISPR-Cas and Abi immunity genes24–26. The
ToxIN Abi system provided strong phage protection, reducing
the EOP by 106 and 105-fold against ɸTE and ɸM1, respectively
(Fig. 1b). For both phages, only 1% of phage-infected cells
harbouring ToxIN released any new viral progeny (Fig. 1c) and
the average burst size was undetectable (Fig. 1d). As expected for
a post-adsorption phage resistance mechanism, ToxIN had no
effect on adsorption (Supplementary Table 1). The outcomes of
ToxIN and CRISPR-Cas-mediated immunity on the different
aspects of infection were therefore qualitatively similar with
respect to phage adsorption and ampliﬁcation.
The type I–F CRISPR-Cas system does not enable cell survival.
Next, we assessed cell survival of bacteria with CRISPR-Cas
immunity upon infection with the virulent phages. Surprisingly,
CRISPR-Cas immunity provided no enhancement in cell survival
measured in single-cell viable count assays compared with the
phage-sensitive WT or the ToxIN Abi system (Fig. 2a), regardless
of the multiplicities of infection (MOI) that were used (Supple-
mentary Fig. 2A). To further investigate cell survival, we assessed
membrane integrity and cellular metabolic activity of phage-
infected cells (Fig. 2b, c, Supplementary Fig. 2B and C). Phage
infection led to signiﬁcant reductions in both membrane integrity
and cellular metabolism even in the presence of CRISPR-Cas or
ToxIN immunity. As a control, surface mutants (i.e. bacteria
carrying mutations in the phage receptor genes on the bacterial
cell surface) were isolated that were resistant to either phage. As
expected for adsorption inhibition, surface resistance against
either phage resulted in cells retaining membrane integrity and
metabolic activity upon phage challenge, but not when challenged
with a phage that uses a different receptor (Supplementary Fig. 3).
Together, we see that phage adsorption is not affected, but rather
phage replication is interrupted by CRISPR-Cas, which results in
fewer phage progeny and leads to the death of the infected cell.
Hence the immunity seen with the type I–F system in P. atro-
septicum fulﬁls the deﬁnition of abortive infection19,20.
Increased CRISPR-Cas resistance does not enhance cell survi-
val. One possible explanation why CRISPR-Cas did not promote
survival following infection, resulting in abortive infection, could
be due to an insufﬁcient immune response, leading to incomplete
phage clearance. For example, anti-CRISPR proteins might
reduce defence and prevent effective phage clearance27,28. How-
ever, the fact that abortive infection occurred with two unrelated
phages and we could not bioinformatically detect known anti-
CRISPRs argues against this theory. Another possibility is that the
CRISPR-Cas components are limiting. Indeed, since the phage-
targeting spacers are in CRISPR arrays that carry 30 (CRISPR1)
and 11 (CRISPR2) other spacers, most effector complexes will be
loaded with non-phage-targeting crRNAs. To explore if an
increased abundance of Cas complexes loaded with phage-
targeting crRNAs would result in survival of infected cells, phage-
targeting spacers were overexpressed from plasmids in the pre-
sence or absence of Cas overexpression (Fig. 3). Increased phage-
targeting crRNAs signiﬁcantly boosted phage resistance com-
pared with chromosomal expression, and induction of Cas
expression further enhanced resistance, by up to ~104–107 fold
compared to the WT (Fig. 3a). However, no marked restoration
in cell survival was detected compared with the sensitive WT
strain (Fig. 3b).
While these data show that CRISPR-immune bacteria do not
survive virulent phage infection even under artiﬁcially high
CRISPR expression levels, it is unclear whether this is due to cell
death induced by CRISPR-Cas components (analogous to the
dormancy observed for type VI systems10), or due to the phage,
which may express lethal genes prior to clearance of the infection.
To explore this question, we examined the outcome of targeting
plasmid DNA for the cells with CRISPR-Cas immunity (Fig. 3c,
d). The P. atrosepticum CRISPR-Cas system effectively inhibits
transformation and conjugation29, but those assays fail to
assess the outcome for cells eliciting effective CRISPR immu-
nity since they are killed by the antibiotic. To directly test whether
plasmid targeting by the I–F system reduces cell survival in
P. atrosepticum, we induced a mini-CRISPR array with a spacer
targeting a plasmid and assessed total cell counts and plasmid
loss. Plasmid targeting decreased cells bearing the plasmid by
106-fold in 18 h but did not decrease total cell numbers. Hence,
these experiments show that the combination of both phage
infection and CRISPR-Cas targeting is required for abortive
infection, since cells survived plasmid targeting.
CRISPR-Cas provides population protection at low phage
doses. Even though abortive infection results in the death of the
infected individual, these defence systems may be favoured by
natural selection because of their population-level beneﬁts if these
are predominantly directed at clone mates (i.e. kin selection). To
explore these kin-selected beneﬁts, we compared population
growth of cells carrying CRISPR-Cas or ToxIN (Abi) under
increasing phage pressures (increasing MOIs) (Supplementary
Fig. 4). Phage-sensitive WT P. atrosepticum populations were
susceptible to phages at any MOI. The phage effects on popula-
tion growth were stronger and faster with increasing phage
numbers, but even with an MOI of 0.0001, WT populations
collapsed (Fig. 4a). As predicted for an Abi mechanism, cultures
containing ToxIN grew with low phage doses, but when phages
equalled or exceeded bacteria (MOI of 1 or higher) population
growth was inhibited. Likewise, CRISPR-Cas immunity enabled
population growth at low phage doses, but at higher MOIs, the
populations either collapsed when infected with ɸM1, or became
static when infected with ɸTE (Fig. 4a, Supplementary Fig. 4). We
predicted that CRISPR-Cas was providing population-level pro-
tection by reducing the phage epidemic. To test this, the effect of
CRISPR-Cas on phage titres was determined (Fig. 4b). Both
phages replicated extensively on the phage-sensitive WT bacteria,
reaching ~1010–1011 pfu ml−1 irrespective of the initial phage
dosage (Fig. 4b). ToxIN reduced the population phage burden
regardless of the initial phage abundance. CRISPR-Cas immunity
limited the phage epidemic when initial viral abundance was low,
but when initial phage numbers were higher, CRISPR was unable
to suppress the phage burden. In summary, immunity provided
by the type I–F CRISPR-Cas system enables population growth
under low viral load by reducing virulent phage burden, therefore
providing a beneﬁt to the population.
Discussion
Here we show that the P. atrosepticum type I–F CRISPR-Cas
system provides immunity against two virulent phages through
abortive infection. Abortive infection systems are diverse, being
deﬁned phenotypically based on their impact on phages, cells and
host populations following infection. Speciﬁcally, phage devel-
opment is impeded, with fewer progeny released and the infected
cells die, which provides population-level protection due to the
decreased phage burden19,20. Indeed, phage-infected cells har-
bouring CRISPR-Cas immunity did not survive (Fig. 2), but this
led to reduced phage propagation (Fig. 1) and the population was
protected due to the reduced phage epidemic (Fig. 4).
The proposed dormancy or possible ‘suicidal’ responses upon
phage infection in bacteria harbouring some CRISPR-Cas var-
iants, were suggested to occur through several mechanisms30.
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These include activation of toxic domains in some Cas proteins,
such as Cas231, collateral ssDNase activity of type V systems14,
promiscuous RNA-targeting by type III11–13 and type VI10 sys-
tems, and self-targeting due to increased spacer acquisition upon
CRISPR-Cas activation32. These models cannot explain abortive
infection by type I–F system and are ruled out by our CRISPR-
Cas plasmid targeting experiments (Fig. 3). Moreover, P. atro-
septicum Cas2 has no detectable nuclease (i.e. toxic) activity33 and
although we have observed acquisition of self-targeting spacers,
this low frequency is unlikely to signiﬁcantly impact cell survi-
val34. Instead, we propose that CRISPR-Cas immunity still
enables a window of time for the virulent phage to express toxic
products or takeover host resources and machinery18. Although
CRISPR-Cas limits phage propagation, the initiation of host-
takeover renders cells unable to recover, and abortive infection
ensues. Although the mechanism of takeover by ɸM1 and ɸTE is
unknown, ɸM1 encodes its own RNAP, suggesting rapid tran-
scriptional reprogramming, and a ɸM1 gene that triggers ToxIN
immunity is toxic in P. atrosepticum26. Therefore, combined with
the absence of an Abi phenotype during type I–F plasmid
targeting (Fig. 3), our results are entirely consistent with CRISPR-
Cas resistance via phage-induced abortive infection.
We hypothesise that the speed and strength of bacterial take-
over and the pace and level of CRISPR-Cas immunity will
inﬂuence the outcome for the infected individual. Indeed, type
I–E and I–F CRISPR-Cas systems can also provide phage resis-
tance without apparent Abi phenotypes16,35. However, these
CRISPR-Cas responses to phages have typically been studied
using ﬁlamentous phages or virulent mutants of temperate phages
(i.e. obligately lytic)16,35,36. Temperate phages can transmit both
horizontally and vertically and therefore generally avoid
immediate early expression of genes involved in host takeover
until the lytic-lysogeny decision is made37. Temperate mutants
locked in an obligately lytic state will initially proceed similarly to
their progenitor temperate phages, but inevitably always make the
same lytic ‘decision’. Filamentous phages cause chronic infections
where bacteria are alive and secrete new phages. For these less
‘aggressive’ phages, CRISPR-Cas may have sufﬁcient time to clear
the infection before phage-induced damage becomes irreversible.
Whereas in virulent phage infection, early expressed genes can
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Fig. 2 The type I–F CRISPR-Cas system does not enable survival of infected cells. a Cell survival was assessed for the WT, 1× and 3× anti-ɸ strains, and
ToxIN, using both ɸTE and ɸM1 (infected at an MOI of 2). b The percentage of cells with intact membranes was determined using LIVE/DEAD™ staining
and c the percentage of metabolically active cells was assessed using the resazurin dye. For b and c cells were infected at an MOI of 2.5. Solid outline bars
represent mock infected samples, dashed outline bars represent phage-infected samples. Data shown are the mean+ one SD. Statistical signiﬁcance was
calculated using one-way ANOVA using Dunnett’s multiple comparison test, comparing strains with targeting spacers to the control with no-targeting
spacers. No signiﬁcance was detected, unless indicated (*p≤ 0.05). Source data are provided as a Source Data ﬁle.
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lead to host DNA degradation, inhibition of host RNA poly-
merase and other effects38,39. We propose that in our study,
CRISPR-Cas was unable to clear the infection before phage-
inﬂicted cellular damage occurred. This helps explain previous
observations that type I–E immunity against T7 or T5 virulent
phages slowed or inhibited the growth of Escherichia coli18.
It is not clear how CRISPR-Cas systems that elicit abortive
infection acquire new spacers. However, spacers might be
acquired from defective phages40 and enable resistant populations
to arise in structured environments21. Indeed, Abi systems evolve
in spatially structured niches where clone mates beneﬁt
directly21,41,42 and we predict that CRISPR-Cas systems that
function through abortive infection will be beneﬁcial under these
conditions. Hence, different CRISPR-Cas variants are likely to be
beneﬁcial in different ecological settings and will depend on the
lifecycle of infecting phages3.
Our demonstration that the type I–F system elicits abortive
infection broadens the view of how CRISPR-Cas immunity is
mediated—sometimes coming at the expense of the individual,
but beneﬁtting the population. We propose that the strength and
speed of host-takeover by the invader and the relative efﬁciency of
resistance are likely to inﬂuence whether CRISPR-Cas provides
protection to the infected individual and the population, or just to
the population via aborted infection. Therefore, virulent phages
are more likely to elicit abortive infection, whereas temperate and
ﬁlamentous phages, or other mobile genetic elements, will be
more likely be cleared. These outcomes may be the extremes of a
continuum that is further inﬂuenced by temporal factors and
invader vs host immune strength, and will need to be factored in
to ecological and evolutionary analyses of CRISPR-Cas immunity.
Methods
Bacterial strains, plasmids and culture conditions. Bacterial strains and plasmids
are listed in Supplementary Table 2. P. atrosepticum SCRI104343 was grown at 25 °C
and Escherichia coli at 37 °C in Lysogeny Broth (LB) at 180 rpm or on LB-agar (LBA)
plates containing 1.5% (w v−1) agar. Minimal media contained 40mM K2HPO4,
14.6 mM KH2PO4, 0.4 mM MgSO4, 7.6mM (NH4)2SO4 and 0.2% (w v−1) glycerol.
When required, media were supplemented with ampicillin (Ap, 100 µgml−1),
kanamycin (Km; 50 µgml−1), isopropyl-ß-D-thiogalactopyranoside (IPTG, 0.1mM),
glucose (glu, 0.2% (v v−1)) and arabinose (ara, 0.2% (v v−1)). Bacterial growth was
measured in a Jenway 6300 spectrophotometer at 600 nm (OD600). All experiments
were performed in a minimum of biological triplicates and data shown are the
mean+ standard deviation.
Phage storage and titration. The phages, ɸTE25 (genome size of ~142 kb) and
ɸM126,44 (genome size of ~43 kb), were stored in phage buffer (10 mM Tris-HCl
pH 7.4, 10 mM MgSO4 and 0.01% w v−1 gelatin). Phage stocks were titrated by
serially diluting phages in phage buffer, adding to 100 µl of P. atrosepticum culture
(pre-grown in 5 ml LB overnight) in 4 ml top LBA (0.35% (ɸTE) and 0.5% (ɸM1)
agar) and pouring onto LBA plates. Plates were incubated at 25 °C overnight,
plaques were counted and the titre determined as plaque forming units (pfu) ml−1.
Efﬁciency of plating (EOP) was calculated as: (pfu ml−1 (test strain)/pfu ml−1
(control strain, P. atrosepticum)). For the following assays (excluding the assays
with the crRNA and Cas overexpression), strains carried the vector, pBR322, to
control for ToxIN (which is on the pBR322 derivative, pTA46).
Efﬁciency of centre of infection assays (ECOI). Overnight cultures were OD-
adjusted and 1 ml was used to inoculate a 25 ml culture in a 250 ml ﬂask, for a
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Fig. 3 CRISPR-Cas overexpression increases phage resistance but infected cells do not survive. a Phage resistance (EOP) and b cell survival was assessed
for WT (with empty vector, pPF975) “WT”, 1× anti-ɸ (PCF190 for ɸTE/PCF254 for ɸM1 (with empty vector), chromosomally expressed) “anti-ɸ”, 1× anti-
ɸ plasmid expressed (WT carrying pPF1423 for ɸTE/pPF1421 for ɸM1) “anti-ɸ (plasmid)”, Cas overexpression (PCF610 (with empty vector)) “Cas+” and
Cas overexpression with 1× anti-ɸ plasmid expressed (PCF610, pPF1423 for ɸTE/pPF1421 for ɸM1) “Cas+, anti-ɸ (plasmid)”. Solid outline bars represent
mock infected samples, dashed outline bars represent phage-infected samples. c Efﬁciency of plasmid maintenance (EOPM) and d cell survival was
assessed for strains carrying pTargeted (with the expI gene) and pControl (inducible mini-CRISPR array with no anti-expI spacer) “Control” or pTargeted
and pCRISPR (anti-expI spacer) “anti-plasmid”. Solid outline bars represent CRISPR repressed samples, dashed outline bars represent CRISPR induced
samples. Data shown are the mean+ one SD. Statistical signiﬁcance was calculated using one-way ANOVA using Dunnett’s multiple comparison test,
comparing strains with targeting spacers to the control with no-targeting spacers. The Cas overexpression and Cas overexpression with 1× anti-ɸ plasmid
expression strains, as well as the strains in d, were compared using an unpaired T-test. No signiﬁcance was detected, unless indicated *p≤ 0.05). Source
data are provided as a Source Data ﬁle.
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starting OD600 of 0.1. Cells were grown until early stationary phase (OD600 of ~0.3)
before 109 total phages (~4 × 107 pfu ml−1) were added at a multiplicity of infection
(MOI) of ~0.1 and cultures were incubated with shaking for 20min. Aliquots of 1ml
were extracted, washed twice in 1 × phosphate-buffered saline (PBS), diluted and
plated in top LBA with P. atrosepticum before the infected cells starting lysing. The
pfu ml−1 was determined for each strain and since each plaque was formed from the
phages released from an individual cell, the titre represents the number of infectious
centres formed. The ECOI was calculated as (pfu ml−1 (test strain)/pfu ml−1 (control
strain, P. atrosepticum)). Spontaneous ɸ-resistant surface mutants, PCF333 and
PCF334, were included to control for unadsorbed phages.
One-step growth curves. Overnight cultures were OD-adjusted and 1 ml was used
to inoculate a 25 ml culture in a 250 ml ﬂask, for a starting OD600 of 0.1. Cells
were grown until early exponential phase (OD600 of 0.25–0.35) and 109 total phages
(~4 × 107 pfu ml−1) were added, for an MOI of ~0.1. Duplicate samples were taken
at various timepoints, until 70 min post infection. One sample was plated imme-
diately (non-treated sample, free phages and phage-infected cells), while the second
was added to phage buffer containing chloroform (treated sample, free phages and
phage accumulated inside infected cells), which lysed the cells, allowing the
assessment of the total number of mature phages at each time point. Samples were
diluted in phage buffer and plated in top LBA with P. atrosepticum. Phage
adsorption over time was determined from the treated samples using the equation
((pfu ml−1 (t= 0)− pfu ml−1 (t= 0–70)/pfu ml−1 (t= 0)). The average phage
burst size was also calculated from the treated samples, as number of phages
released ((pfu ml−1 (t= 70)− pfu ml−1 (t= 30))/the number of cells infected
((pfu ml−1 (t= 0)− pfu ml−1 (t= 30)). The latent period was determined from
the treated samples as was deﬁned as the time before the phage burst starts.
Cell survival assays. Cells were grown to OD600 ~ 0.3 and for each culture, 1 ml
was transferred into two universals. One culture was infected with phages at a MOI
of ~2, while the other was mock infected, with phage buffer. Cultures were shaken
at 180 rpm for 20 min for phages to adsorb and then cells were pelleted and
resuspended in PBS to remove unadsorbed phages. Finally, cells were diluted and
100 µl samples were plated prior to the phage burst (40 min). Cell survival was
calculated as (colony forming units (cfu) ml−1 (phage treated sample)/cfu ml−1
(mock treated sample).
To assess cell survival at a range of MOIs, 100 µl of each exponential phase
culture was aliquoted into eight wells of a 96-well ﬂat-bottomed plate for the
addition of 10 µl phages at seven MOIs as well as a mock infection control (phage
buffer). Cultures were shaken for 20 min for phages to adsorb, and to reduce the
burden of secondary infection, a viricidal solution called TEAF (per ml: 680 µl of
4.3 mM FeS04, 320 µl 7.5% (w v−1) green tea solution (ﬁlter-sterilised)45) was then
added, at a ratio of 75% (v v−1) to each culture. The cultures were then diluted,
more TEAF was added to each dilution and cells were plated as 5 µl spots. Survival
for the ɸTE-infected cells was higher than predicted from the MOIs used,
suggesting that despite high adsorption rates (Supplementary Table 1), the phage
was not able to infect as well in these 96-well assays with high phage doses.
LIVE/DEAD staining for membrane activity. Cell membrane integrity was
assessed using the LIVE/DEAD™ BacLight™ bacterial viability kit, consisting of two
nucleic acid stains, syto-9 and propidium iodide (Life technologies™). Cultures were
prepared for LIVE/DEAD™ staining as described above for the cell survival assays
performed at a range of MOIs. Cells were infected for one hour, to allow for one
complete round of infection, before being stained, according to the manufacturers’
instructions. Culture ﬂuorescence was measured using a Thermo Scientiﬁc™ Var-
ioskan™ plate reader, with excitation/emission wavelengths of 485/530 nm for styo-
9 and 485/630 nm for propidium iodide. Cultures of exponentially growing cells
and cells killed with 70% isopropanol were combined at different ratios to generate
a standard curve, from which the percentage of cells with intact membranes at each
phage MOI could be determined.
Resazurin assays for cell activity. For assays assessing cell activity after one
round of phage infection, cultures were prepared as described above for the cell
survival assays performed at a range of MOIs. Cells were infected for one hour
before resazurin solution was added at a ﬁnal concentration of 0.005% (w v−1).
Cellular oxidoreductases reduce the blue indicator to resoruﬁn, which is pink.
Resoruﬁn ﬂuorescence was measured 30 min after it was added using a Thermo
Scientiﬁc™ Varioskan™ plate reader with excitation/emission wavelengths of 510/
535 nm. Cells for the standard curve were prepared as described for the LIVE/
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DEAD™ staining, from which the percentage of metabolically active cells at each
MOI was determined. Cell activity was assessed, following the 16 h growth assays,
in the same way.
Isolation of spontaneous phage-resistant surface mutant strains. ɸTE and
ɸM1 were plated on P. atrosepticum and cells from colonies that formed in the
centre of plaques were streaked to single colonies. Since ɸTE is ﬂagella-trophic46,
clones isolated from plates with ɸTE were patched onto tryptic swimming agar
(10 g Bacto tryptone, 5 g NaCl, 3 g agar, per litre) to assess ﬂagella-mediated
swimming. A clone that did not swim (PCF333, Supplementary Table 2) was
resistant to ɸTE, but sensitive to ɸM1, which does not use the ﬂagella for infection,
suggesting that it was a surface mutant. A clone isolated from a ɸM1 plaque
(PCF334, Supplementary Table 2) was ɸM1-resistant, but sensitive to ɸTE.
Construction of the plasmids expressing crRNAs. Spacers present in strains
targeting ɸTE (PCF190) and ɸM1 (PCF254) were cloned into pPF975. Over-
lapping primers containing the spacer sequences were annealed and ligated into the
BsaI site in the mini-CRISPR array (repeat-repeat loci) as previously described47 to
form the plasmids, pPF1421 and pPF1423 (Supplementary Table 2). Oligonu-
cleotide sequences are listed in Supplementary Table 3. All plasmids used in this
study were conﬁrmed by sequencing. In assays using these plasmids, their
expression was induced with IPTG.
Construction of the cas overexpression strains. The chromosomal cas over-
expression strain (PCF610) was made by conjugating the suicide vector, pPF1814,
into P. atrosepticum. The vector, pPF1814 was constructed as follows: pSEVA511 was
digested with NotI and ligated with the T5/lac promoter and multiple cloning site
(MCS) from pQE-80L-stuffer, which had been ampliﬁed with PF3494 and PF3495
and digested with NotI. The lacI gene was ampliﬁed from pQE-80L-stuffer (PF2511,
PF2512) and ligated into the MCS at XmaI and SalI sites. Finally, the ﬁrst 500 bp of
cas1 was ampliﬁed using PF357 and PF669 and ligated into EcoRI and XmaI sites in
the MCS. In assays using these strains, their expression was induced with IPTG.
Plasmid targeting assay. The effect of plasmid targeting on cell survival was
assessed using a two-plasmid setup. The ﬁrst plasmid was either a control vector
(pControl, pPF445, ApR) with an inducible mini-CRISPR array with a single repeat
or pCRISPR (pPF452, ApR) carrying a spacer targeting expI. The second plasmid
was pTargeted (pPF459, KmR), which carried the targeted expI gene. pTargeted was
made by PCR-amplifying expI from P. atrosepticum with PF314 and PF317,
digesting the product with BamHI and PstI and ligating the product into the same
sites in pPF260 (KmR-pQE-80L derivative). pControl and pCRISPR were made
previously48. P. atrosepticum ΔexpI (PCF81) was co-transformed with pTargeted
and pCRISPR, or pControl, under CRISPR repressing conditions (0.2% glu) with
both antibiotics (Km and Ap). These strains were for 6 h in LB, 0.2% glu, Ap+Km
with shaking. Cells were pelleted by centrifugation, washed and the culture was
split into two samples, repressed (0.2% glu and Ap) and induced CRISPR condi-
tions (0.2% ara and Ap). Following growth for a further 18 h, cells were plated onto
Ap (for total cell counts) and Km (for targeted vector-containing cell counts).
Efﬁciency of plasmid maintenance was calculated from the Km counts as (cfu ml−1
(pCRISPR)/cfu ml−1 (pControl)). Cell survival was calculated for each strain as
(cfu ml−1 (induced)/cfu ml−1 (repressed). The cell counts for the induced CRISPR
conditions were higher because the growth rate of P. atrosepticum was increased
with supplemented arabinose.
Bacterial population growth assays. P. atrosepticum cultures were grown to an
OD600 of 0.3 and 100 μl was transferred to each well (of a 96-well plate). Phages
were added in 10 μl at multiplicities of infection (MOIs) ranging from 0.0001 to 10
and cultures were grown in a Thermo Scientiﬁc™ Varioskan™ plate reader with
shaking at 480 rpm. Cell density was monitored for 16 h, measuring OD600 every
12 min. Following growth, ﬁnal phage titres were determined by chloroform
treating the bacterial cultures and titrating the phages. The data were processed
using GraphPad Prism to generate restricted cubic spline curves (324 points were
calculated).
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The source data underlying Figs. 1–4 and Supplementary Figs. 1–4 are provided as a
Source Data ﬁle. The data that support the ﬁndings of this study are available in this
article and its Supplementary Information ﬁles, or from the corresponding author upon
request.
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